SCHEMBL2275944

SCHEMBL2275944

CSc1cccc(C2(O)CCNCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.45
SIGMAR1 Q99720 1/20 0.40
OPRM1 P35372 5/20 0.38
ALOX5 P09917 1/20 0.35
OPRK1 P41145 3/20 0.34
OPRL1 P41146 3/20 0.34
OPRD1 P41143 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
CFTR P13569 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734923 0.83 SLC6A4 (0.37) OPRM1OPRK1OPRL1OPRD1MEN1
SCHEMBL9528041 0.80 DRD2 (0.59) DRD2SIGMAR1OPRM1OPRK1OPRL1
SCHEMBL614812 0.79 MEN1 (0.43) OPRM1ALOX5OPRK1OPRL1OPRD1
SCHEMBL2270948 0.78 OPRM1 (0.52) DRD2SIGMAR1OPRM1OPRK1OPRL1
Hydrochloric Acid SCHEMBL9528130 0.78 DRD2 (0.58) DRD2SIGMAR1OPRM1OPRD1DRD4
Ethylene SCHEMBL4679116 0.77 MEN1 (0.41) OPRM1ALOX5OPRK1OPRL1OPRD1
SCHEMBL26808310 0.77 KMT2A (0.41) OPRM1ALOX5OPRD1KMT2A
SCHEMBL613800 0.77 SMN1; SMN2 (0.35) DRD2OPRM1OPRK1OPRL1OPRD1
Hydrochloric Acid SCHEMBL7831551 0.77 OPRM1 (0.51) DRD2SIGMAR1OPRM1OPRK1OPRL1
SCHEMBL6681808 0.76 DRD2 (0.50) DRD2SIGMAR1OPRM1OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 DRD2 3805/4885SIGMAR1 3731/4885OPRM1 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.